Dr. Hongzhou Lu: NAD Management is Key for HIV Patients, Not Just Changing Medication

Dr. Hongzhou Lu: NAD Management is Key for HIV Patients, Not Just Changing Medication

2024.01.14
The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more "efficient and less toxic" treatment options to improve patients' quality of life. At the 12th International AIDS Society HIV Science Conference (IAS 2023) held recently, the first randomized controlled trial on switching to integrase strand transfer inhibitor (INSTI)-based therapy to control weight gain was reported. Infectious Disease Frontier invited Dr. Hongzhou Lu from Shenzhen Third People's Hospital, China, to interpret this trial and share insights into the current and future management of non-AIDS defining diseases (NAD) in HIV-infected individuals.
Dr. Steven Grinspoon: Statin Drugs Can Be Used for Primary Prevention of Cardiovascular Diseases in HIV-Infected Individuals

Dr. Steven Grinspoon: Statin Drugs Can Be Used for Primary Prevention of Cardiovascular Diseases in HIV-Infected Individuals

2023.10.22
Chief of Metabolic Services at Massachusetts General Hospital (MGH), Director of Nutrition Obesity Research Center at Harvard University, and Honorary Chair of Endocrinology and Metabolism at MGH. Dr. Grinspoon led the large-scale, multi-center REPRIEVE study, which is the world's first research on primary prevention strategies for cardiovascular diseases in people living with HIV (PLWH).
Dr. WeiCao: Focus on Managing HIV Complications, Further Improving Patient Survival

Dr. WeiCao: Focus on Managing HIV Complications, Further Improving Patient Survival

2023.10.12
The 12th International AIDS Society Conference on HIV Science (IAS 2023) was held from July 23-26, 2023, in Brisbane, Australia. As the largest open scientific conference in the global field of HIV/AIDS, it attracted the participation of experts, medical professionals, community organizations, and healthcare companies worldwide. Dr. Wei Cao from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, was invited to attend the conference and was interviewed on-site by Infectious Disease Frontier. We have invited Dr. Cao to share the latest developments emerging from this conference and hot topics related to HIV/AIDS treatment.
Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

2023.10.12
The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more "efficient and less toxic" treatment options to improve patients' quality of life. At the 12th International AIDS Society HIV Science Conference (IAS 2023) held recently, the first randomized controlled trial on switching to integrase strand transfer inhibitor (INSTI)-based therapy to control weight gain was reported. Infectious Disease Frontier invited Dr. Hongzhou Lu from Shenzhen Third People's Hospital, China, to interpret this trial and share insights into the current and future management of non-AIDS defining diseases (NAD) in HIV-infected individuals.